Contemporary efficacy of warfarin for afib-related stroke prevention

As new antithrombotics become available, contemporary efficacy of warfarin to reduce afib-related stroke is needed to determine which agents are best for which patients. In this meta-analysis of 8 large RCTs, time spent in therapeutic range was 55% to 68%, and annual risk of stroke was 1.7% per year (higher with higher CHADS2 scores) and risk of bleeding ranged from 1.4% to 3.4% per year. The contemporary statistics can help physicians and patients make the best anticoagulation decisions for stroke prevention (abstract)